Fierce Pharma Asia—Lilly-Abbisko cardiometabolic pact; Daiichi Sankyo asset sale; Eisai's next Alzheimer's prospect

Eli Lilly penned a $258 million R&D pact with Abbisko Therapeutics. Daiichi Sankyo sold U.S. cardiovascular drugs to Cosette Pharma. Eisai's neurology chief talked about its Aduhelm follow-on drug. And more.

Related Keywords

China ,India ,Chinese ,Ridgeback Biotherapeutic ,Ivan Cheung ,Daiichi Sankyo ,Eli Lilly ,Ken Keller ,Bayer Nexavar ,Fosun Pharma ,Merck Co ,Stanford University ,Abbisko Therapeutics ,Cosette Pharma ,Fierce Biotech ,Biogen Partnered Alzheimer ,Accuredit Therapeutics ,United Nations Backed Medicines Patent Pool ,Disai ,Merck Amp Co ,Keytruda ,Olnupiravir ,Cardiovascular Disease ,Alzheimer 039 S ,Liver Cancer ,Pd 1 L1 ,Covid 19 ,Generics ,Pharma ,